Edition:
India

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

2.80USD
22 Nov 2017
Change (% chg)

$-0.01 (-0.36%)
Prev Close
$2.81
Open
$2.76
Day's High
$2.85
Day's Low
$2.65
Volume
34,310
Avg. Vol
29,899
52-wk High
$7.15
52-wk Low
$1.85

Summary

Name Age Since Current Position

John Sedor

72 2016 Chairman of the Board, Chief Executive Officer

Graham Miao

53 2017 President, Chief Financial Officer

Kenneth Pina

59 2017 Senior Vice President, Chief Compliance Officer, General Counsel

John Leone

68 2017 Director

Douglas Swirsky

47 2017 Director

Dennis Langer

66 2016 Independent Director

Gabriel Leung

55 2016 Independent Director

Matthew Duffy

2017 IR Contact Officer

Biographies

Name Description

John Sedor

Mr. John A. Sedor serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Sedor has served as a member of the Board since March 2014. Mr. Sedor has been Chairman and Chief Executive Officer of SEDOR Pharmaceuticals, LLC since 2014 and served as President and CEO and a director of Cangene Corporation, a fully integrated developer and manufacturer of immune therapeutics, from 2011 until its acquisition by Emergent Biosolutions in February 2014. Prior to that, from 2008 until 2011, Mr. Sedor served as Chief Executive Officer and President of CPEX Pharmaceuticals since its spin-off from Bentley in 2008 until its acquisition by Footstar. Mr. Sedor was President of Bentley from 2005 until the spin-off of CPEX. From 2001 to May 2005, he was President and CEO of Sandoz, Inc. (a division of Novartis AG) and prior to that served in a number of senior executive capacities with other healthcare companies.

Graham Miao

Dr. Graham G. Miao, Ph.D., is no longer a President, Chief Financial Officer of the Company effective December 31, 2017. He is currently serves as President, Chief Financial of the Company. He has served as Pernix's President and Chief Financial Officer since July 2016. He was Senior Advisor to the Pernix interim CEO and Board of Directors from May 2016 to July 2016. Prior to joining Pernix, He served as Executive Vice President, Chief Financial Officer of PDI, Inc., a NASDAQ listed healthcare commercialization and molecular diagnostic company, from October 2014 until March 2016. From September 2011 to September 2014, He served as Executive Vice President and Chief Financial Officer and held the additional role as Co-President and Co-Chief Executive Officer from September 2013 to September 2014 of Delcath Systems, Inc., a NASDAQ traded specialty pharmaceutical and medical device company focused on cancer treatment. From September 2009 until September 2011, Dr. Miao served as Chief of Staff for the Global CFO Organization at Dun & Bradstreet Corporation. Previously, Dr. Miao held senior management roles including EVP and CFO at Pagoda Pharmaceuticals and Vice President of Strategic Planning & Financial Analysis at Symrise Inc. He also worked at Schering-Plough Corporation, serving as division CFO for the company's $3 billion primary care pharmaceuticals franchise. Earlier in his career, Dr. Miao worked as a biotechnology equity analyst at J.P. Morgan and a research scientist at Roche. Dr. Miao earned an M.B.A. in Finance and a Ph.D., M.Phil., M.A. in Biological Sciences from Columbia University, an M.S. in Molecular Biology from Arizona State University, and a B.S. in Biology from Fudan University. Dr. Miao will not stand for re-election at our 2017 Annual Meeting.

Kenneth Pina

Mr. Kenneth Robert Pina serves as Senior Vice President, Chief Compliance Officer, General Counsel of the Company. Most recently, He was a Founder and the Managing Principal of Core Risks Ltd. (CRL), which was acquired by Jardine Lloyd Thompson. His practice focused on corporate compliance and ethics programming, enterprise risk and crisis-management program development and litigation support on behalf of a diverse client base. Prior to joining CRL, Mr. Piña served Senior Vice President, Chief Legal Officer and Secretary for Henkel Corporation, a consumer products and specialty chemical company. Before joining Henkel, he worked at Rhone-Poulenc Rorer Pharmaceuticals Inc., where he held positions of increasing responsibility, including Vice President, General Counsel and Secretary. Mr. Piña received his Juris Doctorate from the Dickinson School of Law, Pennsylvania State University, earned his B.S. degree from the Rutgers University College of Pharmacy. He has served as an adjunct professor of food and drug law at Temple University and as a lecturer in law at the Villanova School of Law. He is also co-editor of the industry text, An Introduction to Food and Drug Law and Regulation (FDLI).

John Leone

Mr. John R. Leone serves as Director of the Company. Mr. Leone is currently an Operating Partner at Madryn Asset Management, an investment platform focused on providing capital to healthcare companies. Madryn was spun out from Visium Asset Management, where he was a Partner from May 2013 to January 2017. Prior to joining Visium, Mr. Leone was a Partner at Paul Capital Healthcare, a private equity firm that managed one of the largest dedicated healthcare funds globally (2007 to 2013). Previously, he served as President and Chief Executive Officer at Cambrex Corporation and as Senior Vice President and Chief Operating Officer of U.S. Commercial Operations at Aventis Pharmaceuticals. Mr. Leone currently serves as the chairman of the board of directors of Windtree Therapeutics, Inc. He received his B.S. degree in Engineering from the U.S. Military Academy at West Point, and his M.B.A. from the University of Colorado.

Douglas Swirsky

Mr. Douglas J. Swirsky serves as Mr. Swirsky was most recently President, CEO and a director of GenVec, Inc., a publicly-traded biotechnology company, a position he held from 2013 through the sale of the company in 2017. He joined GenVec in 2006 as Chief Financial Officer, Treasurer and Corporate Secretary. Prior to joining GenVec, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial's acquisition of the Legg Mason Capital Markets business in 2005. He has also previously held investment banking positions at UBS, PaineWebber and Morgan Stanley. Mr. Swirsky is the Chairman of the board of directors of Fibrocell Science, Inc. and the Chairman of the board of directors of Cellectar Biosciences, Inc. He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky, who will serve as Chair of the Audit Committee of the Pernix Board of Directors, is a certified public accountant and a CFA® charter holder.

Dennis Langer

Mr. Dennis H. Langer, M.D., J.D., serves as Independent Director of the Company. From January 2013 to July 2014 he served as Chairman and Chief Executive Officer of AdvanDx, Inc., a healthcare solutions company. From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Previously, he was President, North America, of Dr. Reddy's Laboratories, Limited, a multinational pharmaceutical company. From September 1994 until January 2004, He held several high-level positions at GlaxoSmithKline plc, and its predecessor, SmithKline Beecham, including most recently as a Senior Vice President of Research and Development. Prior to SmithKline Beecham, He was President and CEO of Neose Technologies, Inc. and before that held R&D and marketing positions at pharmaceutical companies Eli Lilly and Company, Abbott Laboratories and G. D. Searle & Company. At the beginning of his career, he was a Chief Resident at Yale University School of Medicine, and held clinical fellowships at Harvard Medical School and the National Institutes of Health. Dr. Langer currently serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., and several private companies. Dr. Langer served as a Director of several pharmaceutical and biotechnology companies, including Auxilium Pharmaceuticals, Inc., Ception Therapeutics, Inc. (acquired by Cephalon, Inc.), Cytogen Corporation, (acquired by EUSA Pharma, Inc.) Delcath Systems, Inc., Myrexis, Inc. Pharmacopeia, Inc. (acquired by Ligand Pharmaceuticals, Inc.), Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), and Transkaryotic Therapies, Inc. (acquired by Shire plc). Dr. Langer is a Clinical Professor, Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. from Harvard Law School, a M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

Gabriel Leung

Mr. Gabriel S. Leung serves as Independent Director of the Company. He is currently Vice Chairman and Board member of NovoCure Limited, a publically listed commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers. He was most recently Executive Vice President of OSI Pharmaceuticals, Inc. and President of OSI's Oncology and Diabetes Business, from 2003 to 2010, prior to its acquisition by Astellas Pharma Inc. Mr. Leung was responsible for the launch of erlotinib (Tarceva) at OSI. Prior to his tenure at OSI, from 1999 to 2003, He served as Group Vice President of the global prescription business at Pharmacia Corporation, a global pharmaceutical and healthcare company, leading Pharmacia's global oncology franchise in over 80 countries. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company, where he was responsible for the growth of Taxol and Paraplatin. In addition, Mr. Leung served as a director for Albany Molecular Research Inc. (AMRI), a global contract research and manufacturing company, from 2010 to 2016 and as a director of Delcath Systems, Inc. from 2011 to 2014, a specialty pharmaceutical and medical device company. Mr. Leung earned his B.S. in Pharmacy with high honors at the University of Texas at Austin. Mr. Leung attended graduate school at the University of Wisconsin-Madison, where he earned his M.S. in Pharmacy, with a concentration in pharmaceutical marketing.

Matthew Duffy

Basic Compensation

Name Fiscal Year Total

John Sedor

1,927,840

Graham Miao

1,019,470

Kenneth Pina

--

John Leone

--

Douglas Swirsky

--

Dennis Langer

--

Gabriel Leung

--

Matthew Duffy

--
As Of  31 Dec 2016